Currently, systemic thrombolysis with tissue-type plasminogen activator remains the only FDA-approved reperfusion strategy for acute ischemic stroke [4], which must be given during the early onset of stroke and delayed therapy significantly increases the risks of intracranial hemorrhage [5]. This evidence concerns the gene PLAT and stroke disorder.